How to Get Clinical Trial Approval in Venezuela: The Complete INHRR Regulatory Process
A comprehensive guide for international sponsors navigating the INHRR clinical trial authorization process in Venezuela — from document preparation to final approval.
April 24, 2026
14
min read
By
bioaccess® Editorial Team
clinical trial approval Venezuela
INHRR regulatory process
Venezuela clinical trials
INHRR Venezuela
Latin America clinical research
**Key Takeaways**
- • INHRR (Instituto Nacional de Higiene Rafael Rangel) is Venezuela's national regulatory authority for clinical trials
- • Approval timeline: 3-6 months from complete CTA submission to authorization
- • Required documents: Protocol, IB, ICF, ethics approval, financial disclosure, GMP certificates
- • Ethics review must be completed by an institutional ethics committee before INHRR submission
- • bioaccess® is the first CRO to establish clinical trial operations in Venezuela
Overview of clinical trial regulation in Venezuela
Venezuela's clinical trial regulatory framework is governed by the Ministry of Popular Power for Health (MPPS) and implemented through the Instituto Nacional de Higiene Rafael Rangel (INHRR). The country follows international Good Clinical Practice (ICH-GCP) standards, making clinical data generated in Venezuela acceptable to regulatory authorities worldwide, including the US FDA.
As the third-largest medical device market in Latin America, Venezuela offers unique advantages for sponsors seeking to conduct first-in-human clinical trials — including treatment-naïve patient populations, competitive operational costs (40-60% savings versus traditional markets), and a growing pool of GCP-trained investigators.
Despite the country's economic challenges, Venezuela's clinical research infrastructure has maintained high standards. The regulatory process, while less commonly navigated by international sponsors compared to markets like Mexico or Colombia, is well-defined and increasingly accessible — particularly with the support of experienced local partners like bioaccess®.
INHRR's role in clinical trial authorization
The Instituto Nacional de Higiene Rafael Rangel (INHRR) serves as Venezuela's equivalent of the FDA for clinical trial oversight. Established as a specialized technical institute under the MPPS, INHRR is responsible for evaluating clinical trial applications (CTAs), monitoring ongoing studies, and ensuring compliance with national and international regulations.
INHRR's key responsibilities include:
- Reviewing and authorizing clinical trial protocols for drugs, biologics, and medical devices
- Evaluating investigator qualifications and site capabilities
- Monitoring GCP compliance through inspections during and after studies
- Managing adverse event reporting and safety surveillance
- Issuing import authorizations for investigational products
- Maintaining the national clinical trial registry
Unlike some regulatory authorities in the region, INHRR handles both the scientific/medical review and the administrative authorization in a single pathway, which can streamline the overall timeline when submissions are well-prepared.
Required documents for CTA submission
A complete clinical trial application to INHRR must include the following documents, all of which should be translated into Spanish if originally prepared in another language:
Core regulatory documents
- Clinical trial protocol (complete, ICH-compliant version with all amendments)
- Investigator's Brochure (IB) with current safety and efficacy data
- Informed Consent Form (ICF) in Spanish, adapted to Venezuelan regulatory requirements
- Case Report Forms (CRFs) or electronic data capture system documentation
- Statistical analysis plan
- Data Safety Monitoring Board (DSMB) charter, if applicable
Investigator and site documentation
- Principal Investigator CV and medical license documentation
- Sub-investigator CVs and GCP training certificates
- Site facility information and capabilities assessment
- Financial disclosure forms for all investigators
- Laboratory certifications and normal ranges
Product and safety documentation
- GMP certificate for the investigational product manufacturer
- Certificate of Analysis for the investigational product
- Insurance/indemnity documentation covering trial participants
- Previous clinical study reports or safety data summaries
- For medical devices: design documentation and preclinical safety data
Step-by-step submission process
The clinical trial approval process in Venezuela follows a defined pathway. Here is the step-by-step process that sponsors should follow:
| Step | Activity | Estimated Duration |
|---|---|---|
| 1 | Engage local CRO and regulatory consultant | 2-4 weeks |
| 2 | Prepare and translate all CTA documents | 4-6 weeks |
| 3 | Submit to institutional ethics committee | 4-8 weeks |
| 4 | Obtain ethics committee approval letter | 1-2 weeks |
| 5 | Submit complete CTA package to INHRR | 1 week |
| 6 | INHRR scientific and administrative review | 8-16 weeks |
| 7 | Respond to INHRR queries (if any) | 2-4 weeks |
| 8 | Receive INHRR authorization | 1-2 weeks |
| 9 | Obtain IP import authorization | 2-3 weeks |
| 10 | Site activation and first patient enrollment | 2-4 weeks |
Review timelines and what to expect
The total timeline from initial CRO engagement to first patient enrolled in Venezuela typically ranges from 18 to 33 weeks, depending on the complexity of the protocol and the completeness of the initial submission.
The INHRR review phase itself takes approximately 8-16 weeks. During this period, the regulatory authority may issue queries or requests for additional information. Response time to these queries is critical — delays in responding can extend the overall timeline significantly.
**Timeline optimization tip**
The single most effective way to shorten the approval timeline is to ensure the initial submission is complete and well-organized. bioaccess® has found that 80% of delays in INHRR review are caused by incomplete submissions or missing documents. Working with an experienced local CRO eliminates these common pitfalls.
Ethics committee approval requirements
In Venezuela, ethics committee approval must be obtained before submitting the CTA to INHRR. The institutional ethics committee (Comité de Ética de la Investigación) at the clinical trial site reviews the protocol for ethical compliance and patient safety.
Key requirements for ethics committee review include:
- Protocol review for scientific merit and ethical compliance
- Informed consent form review — must be in clear, accessible Spanish
- Risk-benefit assessment for trial participants
- Review of participant compensation and insurance provisions
- Assessment of investigator qualifications and conflict of interest
- Ongoing oversight through annual renewals and amendment reviews
Ethics committees in Venezuela follow PAHO/WHO standards and CIOMS guidelines, ensuring international acceptability of their reviews. For more on ethics committee requirements in Venezuela, see our dedicated guide.
Common delays and how to avoid them
Based on bioaccess®'s experience as the first CRO to establish clinical trial operations in Venezuela, the most common causes of delays in the approval process include:
- Incomplete document translations — all materials must be in Spanish
- Missing or outdated GMP certificates for investigational products
- Inadequate informed consent forms that don't meet Venezuelan requirements
- Delays in obtaining institutional ethics committee approval
- Investigational product import logistics not initiated early enough
- Insufficient insurance/indemnity documentation for trial participants
- Lack of local regulatory representation or sponsor agent
Tips for international sponsors
For pharmaceutical, biotech, medtech, and radiopharma companies considering Venezuela for their clinical programs, bioaccess® recommends the following strategies:
- Engage a local CRO with INHRR experience early — regulatory intelligence saves months
- Start ethics committee and INHRR submissions in parallel where possible
- Ensure all documents are professionally translated into Spanish before submission
- Begin investigational product import logistics at least 8 weeks before planned site activation
- Leverage Venezuela's cost advantages — 40-60% savings vs. traditional markets
- Consider Venezuela as part of a multi-country LATAM strategy with bioaccess®
How bioaccess® supports regulatory submissions in Venezuela
bioaccess® is a CRO exclusively focused on first-in-human clinical trials and was the first CRO to establish clinical trial operations in Venezuela. Our regulatory team provides end-to-end support for INHRR submissions, including:
- Regulatory strategy development and pre-submission consultations
- Complete CTA document preparation, review, and translation
- Ethics committee submission management and follow-up
- INHRR submission and liaison throughout the review process
- Investigational product import authorization and logistics
- Site selection from our network of GCP-trained Venezuelan investigators
- Full clinical operations: monitoring, data management, and safety reporting
**Ready to explore clinical trials in Venezuela?**
Venezuela offers the region's lowest operational costs with access to 60,000+ trained physicians. Contact bioaccess® to discuss your regulatory strategy, or explore our FIH-12™ process for accelerated trial setup across Latin America.
Frequently asked questions
Get your FIH roadmap for Venezuela
bioaccess® has the regulatory expertise and investigator network to launch your clinical trial in Venezuela efficiently.
Get your FIH roadmap
View case studies